Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
about
Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials.Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.
P2860
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@en
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@nl
type
label
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@en
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@nl
prefLabel
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@en
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@nl
P2093
P2860
P1433
P1476
Prognostic value of phosphoryl ...... ted with adjuvant trastuzumab.
@en
P2093
Akiko Mizutoh
Hiroshi Sonoo
Junichi Kurebayashi
Naoki Kanomata
Takuya Moriya
Tetsumasa Yamashita
Toshiro Shimo
P2860
P2888
P304
P356
10.1007/S12282-013-0478-Y
P577
2013-06-08T00:00:00Z